Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence

1 Sept 2015

Abstract excerpt

BACKGROUND: Altered DNA methylation in CpG islands of gene promoters has been implicated in prostate cancer (PCa) progression and can be used to predict disease outcome. In this study, we determine whether methylation changes of androgen biosynthesis pathway (ABP)-related genes in patients' plasma cell-free DNA (cfDNA) can serve as prognostic markers for biochemical recurrence (BCR). METHODS: Methyl-binding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26332453
DOI: 10.1002/pros.23052

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrencePMID 26332453Read ↗

DNA methylation alterations in prostate cancer: from diagnosis to treatmentSemantic proximity Read ↗

Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate CancerSemantic proximity Read ↗

Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancerSemantic proximity Read ↗

Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortalitySemantic proximity Read ↗

Multiple Highly Methylated CpG Sites as Potential Epigenetic Markers for the Diagnosis of Prostate CancerSemantic proximity Read ↗

Global Methylation Profiling for Risk Prediction of Prostate CancerSemantic proximity Read ↗

Genome-Wide Methylation Analysis of Prostate Tissues Reveals Global Methylation Patterns of Prostate CancerSemantic proximity Read ↗

Epigenomic alterations in localized and advanced prostate cancer.Semantic proximity Read ↗

A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancerSemantic proximity Read ↗

A three‐gene DNA methylation biomarker accurately classifies early stage prostate cancerSemantic proximity Read ↗

Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissueSemantic proximity Read ↗

Validation Study of Genes with Hypermethylated Promoter Regions Associated with Prostate Cancer RecurrenceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.